Download the Free Unbound MEDLINE PubMed App to your smartphone or tablet.
Available for iPhone, iPad, iPod touch, and Android:
Available for Mac and Windows Desktops and laptops:
- Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study. [JOURNAL ARTICLE]
- Eur J Neurol 2016 Feb 5.
- IFN beta 1a as Glucocorticoids-Sparing Therapy in a Patient with CLIPPERS. [Journal Article]
- Am J Case Rep 2016.:47-50.
BACKGROUNDChronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) is a recently described inflammatory disease of the central nervous system, distinguished by brainstem- and spinal cord-centered lesions with a characteristic contrast enhancement on MRI, a lymphocytic perivascular infiltrate on pathological exam, and a dramatic response to and dependence on steroids therapy. Since its initial description in 2010, different glucocorticoid-sparing agents, mostly immunosuppressant drugs, have been used to minimize the dosage, but these therapies also carry the risk of important secondary effects. We present the first reported case of CLIPPERS treated with interferon beta 1a as add-on therapy. CASE REPORT A previously healthy 31-year-old man presented with gait ataxia and dysarthria. MRI showed pons-centered hyperintense patchy lesions on T2-weighted images. Additional tests ruled out other possible diagnoses and symptoms reversed with intravenous methylprednisolone. Over the years the patient presented with several episodes of deterioration each year, which were partly reversed with glucocorticoid therapy, but leaving him with growing sequelae. Four years after the initial event, treatment with interferon-beta-1a was initiated, achieving reduced frequency of the relapses to 1 every 4 years, which were no longer associated to increasing disability. This allowed reducing glucocorticoids to 30 mg of Deflazacort every other day.
CONCLUSIONSInterferon beta-1a could be an alternative to corticosteroid-combined therapy in CLIPPERS and its more benign profile of secondary effects compared to immunosuppressants could make it an attractive choice.
- miR-24 Regulates Macrophage Polarization and Plasticity. [JOURNAL ARTICLE]
- J Clin Cell Immunol 2015 Oct; 6(5)
- The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. [Journal Article, Review]
- Ther Adv Neurol Disord 2016 Jan; 9(1):44-52.
- The potential teratogenic effects of interferon beta-1a (IFNβ-1a) and interferon beta-1b (IFNβ-1b) on in vitro embryonic development. [JOURNAL ARTICLE]
- Folia Morphol (Warsz) 2015 Dec 29.
- Deficiency of dietary niacin impaired intestinal mucosal immune function via regulating intestinal NF-κB, Nrf2 and MLCK signaling pathways in young grass carp (Ctenopharyngodon idella). [Journal Article]
- Fish Shellfish Immunol 2016 Feb.:177-93.
- Effect of Inhaled Interferon Beta-1a on Carbon Monoxide Transfer Factor in Healthy Volunteers. [Journal Article]
- J Interferon Cytokine Res 2016 Feb; 36(2):113-9.
- Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta. [Journal Article]
- Neurol Neurochir Pol 2015; 49(6):451-5.
- Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS. [Journal Article]
- Neurol Neuroimmunol Neuroinflamm 2015 Dec; 2(6):e176.
- Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. [Journal Article, Review]
- Ther Adv Neurol Disord 2015 Nov; 8(6):274-93.